Dyne Therapeutics (NASDAQ:DYN) Releases Earnings Results

Dyne Therapeutics (NASDAQ:DYN) announced its earnings results on Tuesday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25), Zacks reports.

Dyne Therapeutics Stock Performance

DYN traded up $3.49 during trading on Wednesday, reaching $32.82. 444,100 shares of the stock were exchanged, compared to its average volume of 1,486,979. The stock’s 50 day moving average price is $32.63 and its two-hundred day moving average price is $35.12. Dyne Therapeutics has a twelve month low of $9.26 and a twelve month high of $47.45. The stock has a market cap of $3.30 billion, a P/E ratio of -8.78 and a beta of 1.10.

Analyst Upgrades and Downgrades

DYN has been the topic of a number of research reports. Morgan Stanley upped their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Oppenheimer restated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday. Finally, JPMorgan Chase & Co. cut Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Dyne Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $50.60.

Insider Activity

In other Dyne Therapeutics news, CEO John Cox bought 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the acquisition, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. The trade was a -100.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, COO Susanna Gatti High sold 8,976 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.41, for a total transaction of $308,864.16. Following the completion of the sale, the chief operating officer now owns 131,636 shares in the company, valued at $4,529,594.76. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO John Cox bought 32,000 shares of the stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average price of $33.04 per share, for a total transaction of $1,057,280.00. Following the purchase, the chief executive officer now owns 8,000 shares of the company’s stock, valued at $264,320. This trade represents a -100.00 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is owned by company insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.